Advertisement

Topics

Bristol Stumbles in Lung Cancer Again as Rivals Play Catch-Up

12:41 EDT 12 Oct 2018 | Xconomy

Nivolumab (Opdivo) recently became the first immunotherapy ever approved for people with small cell lung cancer (SCLC), a particularly aggressive form of the deadly disease. But the lead given to its developer, Bristol-Myers Squibb, may be short-lived. Bristol (NYSE: BMY) said today that its immunotherapy nivolumab (Opdivo) failed a Phase 3 study called Checkmate 331. […]

Original Article: Bristol Stumbles in Lung Cancer Again as Rivals Play Catch-Up

NEXT ARTICLE

More From BioPortfolio on "Bristol Stumbles in Lung Cancer Again as Rivals Play Catch-Up"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...

Lung Cancer
Lung cancer is the uncontrolled cell growth in tissues of the lung. Originating in the lungs, this growth may invade adjacent tissues and infiltrate beyond the lungs. Lung cancer, the most common cause of cancer-related death in men and women, is respons...